Abstract：
Cervical cancer is the most common indication for ovarian transposition in reproductive-age women. Ovarian transposition should be performed in premenopausal women undergoing pelvic irradiation to preserve ovarian function, and prevent early menopause. As women become more knowledgeable about their fertility options, it is still unclear who will benefit from the intervention. We updated our previous meta-analysis of ovarian function preservation, symptomatic ovarian cysts, and metastases to the transposed ovaries following ovarian transposition in cervical cancer patients to further guide current clinical practice.
A systematic search of Medline, Embase, Web of Science, and The Cochrane Library databases, dating from January 1980 to July 2021, was conducted. We computed the summary proportions of women who had ovarian function preservation, non-ovarian cyst formation and metastases to the transposed ovaries following ovarian transposition by random-effects meta-analysis and we explored study heterogeneity by type of radiotherapy.
There were 29 publications reporting on 1160 women with cervical cancer who underwent ovarian transposition. In the group that underwent surgery alone, 91% of the women had preserved ovarian function (95% CI 83-100), 89% (95% CI 80-99) of women who did not develop ovarian cysts, and 99% (95% CI 1-5) of women who did not suffer metastases to the transposed ovaries. In the surgery ± brachytherapy (BR) group, the proportion of women with the preserved ovarian function was 93% (95% CI 76-113), 84% (95% CI 69-103) of women who did not develop ovarian cysts, and 99% (95% CI 82-120) of women who did not suffer metastases to the transposed ovaries. In the external beam pelvic radiotherapy (EBRT) ± BR ± surgery group, the proportion of women with the preserved ovarian function was 61% (95% CI 55-69), and 95% (95% CI 85-107) of women who developed ovarian cysts. There were no metastases to the transposed ovaries in that group.
In women with cervical cancer, ovarian transposition offers a significant preservation of the ovarian function. Despite an expected incidence of ovarian cyst formation, it carries almost no risk for metastases to the transposed ovaries.
A systematic search of Medline, Embase, Web of Science, and The Cochrane Library databases, dating from January 1980 to July 2021, was conducted. We computed the summary proportions of women who had ovarian function preservation, non-ovarian cyst formation and metastases to the transposed ovaries following ovarian transposition by random-effects meta-analysis and we explored study heterogeneity by type of radiotherapy.
There were 29 publications reporting on 1160 women with cervical cancer who underwent ovarian transposition. In the group that underwent surgery alone, 91% of the women had preserved ovarian function (95% CI 83-100), 89% (95% CI 80-99) of women who did not develop ovarian cysts, and 99% (95% CI 1-5) of women who did not suffer metastases to the transposed ovaries. In the surgery ± brachytherapy (BR) group, the proportion of women with the preserved ovarian function was 93% (95% CI 76-113), 84% (95% CI 69-103) of women who did not develop ovarian cysts, and 99% (95% CI 82-120) of women who did not suffer metastases to the transposed ovaries. In the external beam pelvic radiotherapy (EBRT) ± BR ± surgery group, the proportion of women with the preserved ovarian function was 61% (95% CI 55-69), and 95% (95% CI 85-107) of women who developed ovarian cysts. There were no metastases to the transposed ovaries in that group.
In women with cervical cancer, ovarian transposition offers a significant preservation of the ovarian function. Despite an expected incidence of ovarian cyst formation, it carries almost no risk for metastases to the transposed ovaries.
摘要：
宫颈癌是育龄期妇女卵巢移位最常见的指征。卵巢转位应在绝经前妇女进行盆腔照射，以保持卵巢功能，并防止更年期提前。随着女性越来越了解自己的生育选择，尚不清楚谁将从干预中受益。我们更新了以前关于卵巢功能保留的荟萃分析，有症状的卵巢囊肿,子宫颈癌患者卵巢移位后卵巢移位转移，以进一步指导当前的临床实践。
对Medline的系统搜索，Embase,WebofScience,和Cochrane图书馆数据库，从1980年1月到2021年7月，进行了。我们计算了保留卵巢功能的女性的总比例，通过随机效应荟萃分析,我们探讨了非卵巢囊肿形成和卵巢转位后卵巢转位的转移,研究了不同放疗类型的异质性.
有29篇出版物报道了1160名宫颈癌妇女接受卵巢移位。在单独接受手术的组中，91%的女性卵巢功能保留（95%CI83-100），89%（95%CI80-99）的未发生卵巢囊肿的女性，99%(95%CI1-5)未发生卵巢转位转移的女性。在手术±近距离放射治疗（BR）组中，卵巢功能保留的女性比例为93%（95%CI76-113），84%(95%CI69-103)的未发生卵巢囊肿的女性，99%(95%CI82-120)未发生卵巢转位转移的女性。在骨盆外照射（EBRT）±BR±手术组中，卵巢功能保留的女性比例为61%（95%CI55-69），95%（95%CI85-107）的女性发生卵巢囊肿。该组中转座卵巢没有转移。
在患有宫颈癌的女性中，卵巢转位提供了一个显着的保护卵巢功能。尽管卵巢囊肿形成的预期发生率，它几乎没有转移到转座卵巢的风险。
对Medline的系统搜索，Embase,WebofScience,和Cochrane图书馆数据库，从1980年1月到2021年7月，进行了。我们计算了保留卵巢功能的女性的总比例，通过随机效应荟萃分析,我们探讨了非卵巢囊肿形成和卵巢转位后卵巢转位的转移,研究了不同放疗类型的异质性.
有29篇出版物报道了1160名宫颈癌妇女接受卵巢移位。在单独接受手术的组中，91%的女性卵巢功能保留（95%CI83-100），89%（95%CI80-99）的未发生卵巢囊肿的女性，99%(95%CI1-5)未发生卵巢转位转移的女性。在手术±近距离放射治疗（BR）组中，卵巢功能保留的女性比例为93%（95%CI76-113），84%(95%CI69-103)的未发生卵巢囊肿的女性，99%(95%CI82-120)未发生卵巢转位转移的女性。在骨盆外照射（EBRT）±BR±手术组中，卵巢功能保留的女性比例为61%（95%CI55-69），95%（95%CI85-107）的女性发生卵巢囊肿。该组中转座卵巢没有转移。
在患有宫颈癌的女性中，卵巢转位提供了一个显着的保护卵巢功能。尽管卵巢囊肿形成的预期发生率，它几乎没有转移到转座卵巢的风险。
